NeuroBo Pharmaceuticals, Inc. is set to discuss key pre-clinical findings of its novel drugs DA-1241 and DA-1726 which address significant cardiometabolic issues such as obesity and MASH, at major upcoming scientific conferences.
In a remarkable stride within the field of cardiometabolic health, NeuroBo Pharmaceuticals, Inc., a Cambridge-based biotechnology firm, is set to present pivotal pre-clinical data on two of its drugs, DA-1241 and DA-1726, at prestigious scientific gatherings this June. These conferences include the European Association for the Study of the Liver (EASL) Congress 2024 in Milan, Italy, and the 84th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, FL, USA.
DA-1241 stands as NeuroBo’s innovative response to metabolic dysfunction-associated steatohepatitis (MASH), a severe form of non-alcoholic fatty liver disease that is often linked to metabolic syndrome and is characterized by inflammation and liver cell damage. As a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, DA-1241 has already seen completion of enrollment for Part 1 of its Phase 2a clinical trial. Pre-clinical research presented by the company illustrates that DA-1241, particularly when combined with Semaglutide, an already established treatment, markedly improves liver fibrosis in diseased mice.
On the other hand, DA-1726 approaches obesity treatment through a sophisticated mechanism, functioning as a dual oxyntomodulin (OXM) analog agonist, targeting both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). This dual approach has shown consistent preclinical success by potentially enabling significant weight loss through decreased food consumption and increased energy expenditure. The first patient has been dosed in the single ascending dose portion of their Phase 1 trial, with further results and developments planned for the near future.
The decision of NeuroBo to pioneer these drugs underlines a crucially growing need for new treatments in the cardiometabolic domain, which encompasses a range of serious health issues including obesity, type 2 diabetes, and various liver diseases. Both DA-1241 and DA-1726 leverage the therapeutic potential of gut hormones, which play vital roles in managing energy balance and metabolism.
The implications of NeuroBo’s research are far-reaching. Obesity and MASH are burgeoning health concerns globally, with significant impacts on quality of life and substantial healthcare costs. The World Health Organization has flagged obesity as a major risk factor for a number of chronic diseases, including diabetes, cardiovascular diseases, and cancer.
NeuroBo’s presentations at these influential meetings are not just a platform to unveil scientific data but also an opportunity to attract attention from potential collaborators and investors who could aid in the rapid development and availability of these innovative treatments.
These comprehensive efforts by NeuroBo signal a promising horizon in the management and treatment of complex, chronic conditions linked to metabolic health, aligning with broader medical needs and ongoing research that targets the improvement of life quality for patients worldwide. As these drugs progress through clinical trials, the medical community and potential patients keenly await further results that could herald new, effective treatment options in the fight against cardiometabolic diseases.
